BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 11230467)

  • 1. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.
    Doyle C; Crump M; Pintilie M; Oza AM
    J Clin Oncol; 2001 Mar; 19(5):1266-74. PubMed ID: 11230467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost.
    Patnaik A; Doyle C; Oza AM
    Anticancer Drugs; 1998 Nov; 9(10):869-78. PubMed ID: 9890698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resource implications of palliative chemotherapy for ovarian cancer.
    Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
    J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does palliative chemotherapy really palliate and are we measuring it correctly? A mixed methods longitudinal study of health related quality of life in advanced soft tissue sarcoma.
    Gough N; Koffman J; Ross JR; Riley J; Judson I
    PLoS One; 2019; 14(9):e0210731. PubMed ID: 31557183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.
    Raman S; Ding K; Chow E; Meyer RM; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JSY; Nabid A; Haas R; Wiggenraad R; Babington S; Demas WF; Wilson CF; Wong RKS; Zhu L; Brundage M
    Qual Life Res; 2018 Apr; 27(4):1089-1098. PubMed ID: 29188483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in ovarian cancer patients receiving chemotherapy.
    Lakusta CM; Atkinson MJ; Robinson JW; Nation J; Taenzer PA; Campo MG
    Gynecol Oncol; 2001 Jun; 81(3):490-5. PubMed ID: 11371144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
    King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML
    Int J Gynecol Cancer; 2014 Jun; 24(5):865-73. PubMed ID: 24844220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
    Park KU
    Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-cultural verification of the EORTC QLQ-C15-PAL questionnaire in mainland China.
    Zhang L; Wang N; Zhang J; Liu J; Luo Z; Sun W; Woo SM; Chen C; Zhang K; Miller AR; Guo H; Zhang X; Wang C
    Palliat Med; 2016 Apr; 30(4):401-8. PubMed ID: 26121985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
    Carey MS; Bacon M; Tu D; Butler L; Bezjak A; Stuart GC
    Gynecol Oncol; 2008 Jan; 108(1):100-5. PubMed ID: 17920108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The European Organization for Research and Treatment of Cancer core quality of life questionnaire (QLQ-C30 version 3.0 Turkish) in cancer patients receiving palliative radiotherapy.
    Hiçsönmez A; Köse K; Andrieu MN; Güney Y; Kurtman C
    Eur J Cancer Care (Engl); 2007 May; 16(3):251-7. PubMed ID: 17508945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of overall well-being using the EORTC QLQ-C15-PAL extracted from the EORTC QLQ-C30.
    Lam K; Zeng L; Zhang L; Tseng LM; Hou MF; Fairchild A; Vassiliou V; Jesus-Garcia R; Alm El-Din MA; Kumar A; Forges F; Chie WC; Sahgal A; Poon M; Chow E
    J Palliat Med; 2013 Apr; 16(4):402-8. PubMed ID: 23458649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responsiveness to change in health-related quality of life in a randomized clinical trial: a comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module. European Organization for Research and Treatment of Cancer.
    Stockler MR; Osoba D; Goodwin P; Corey P; Tannock IF
    J Clin Epidemiol; 1998 Feb; 51(2):137-45. PubMed ID: 9474074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer.
    Kim JW; Kim JG; Kang BW; Chung IJ; Hong YS; Kim TY; Song HS; Lee KH; Zang DY; Ko YH; Song EK; Baek JH; Koo DH; Oh SY; Cho H; Lee KW
    Cancer Res Treat; 2019 Jan; 51(1):223-239. PubMed ID: 30584995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EORTC QLQ-C30 and FACT-Lym for the assessment of health-related quality of life of newly diagnosed lymphoma patients undergoing chemotherapy.
    Georgakopoulos A; Kontodimopoulos N; Chatziioannou S; Niakas D
    Eur J Oncol Nurs; 2013 Dec; 17(6):849-55. PubMed ID: 23850411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study.
    Creutzfeldt A; Suling A; Oechsle K; Mehnert A; Atanackovic D; Kripp M; Arnold D; Stein A; Quidde J
    BMC Palliat Care; 2016 Mar; 15():25. PubMed ID: 26928745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life and symptom evaluation in daily oncology practice: a survey of 150 patients with advanced gastrointestinal tumours receiving palliative chemotherapy.
    Schultheis K; Hofheinz RD; Gencer D; Blunk JA; Benrath J
    Onkologie; 2013; 36(1-2):33-7. PubMed ID: 23429329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octreotide for palliative treatment of hepatic metastases from non-neuroendocrine primary tumours: evaluation of quality of life using the EORTC QLQ-C30 questionnaire.
    Pistevou-Gombaki K; Eleftheriadis N; Plataniotis GA; Sofroniadis I; Kouloulias VE
    Palliat Med; 2003 Apr; 17(3):257-62. PubMed ID: 12725479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.